



Crescendo Biologics shortlisted for Biotech and Money 2017 Awards

Cambridge, UK, 12 June 2017 – Crescendo Biologics Limited (Crescendo), the developer of multi-functional Humabody® therapeutics, is pleased to have been nominated as a finalist in three of the Biotech and Money 2017 Awards.

The categories are:

- UK Growth Life Science Company of the Year,
- UK Life Science Deal of the Year, and
- UK Life Science CEO of the Year.

The Biotech and Money 2017 [Assembly and Awards Gala Dinner](#) celebrates the best of the UK Life Sciences sector and in particular funding, finance and investment successes over the past 12 months.

Crescendo has been nominated for its transition from a technology platform company to a developer of Humabody® therapeutics; the Company has created a rich internal pipeline of truly differentiated, multi-functional biologics with a focus on oncology. The Company's innovative approach was validated last October through a commercial partnership with Takeda worth up to US\$790m.

The winners in each category are determined 50% by online voting and 50% by a live vote on the night of the Awards dinner, which is held in London on 14 September. Voting is now open [here](#).

Details of the awards dinner and ceremony are as follows:

Biotech and Money 2017 Assembly and Awards Gala Dinner

Date: Thursday 14 September 2017

Time: 18:00 to 23:00

Location: Merchant Taylors Hall, 30 Threadneedle Street, London, EC2R 8JB

Ends

For more information, please contact:

Crescendo Biologics
Dr Peter Pack, CEO

Tel:44 (0)1223 497140
info@crescendobiologics.com

Instinctif Partners
Dr Christelle Kerouedan / Melanie Toyne-Sewell

Tel:44 (0)20 7457 2020
crescendo@instinctif.com

Notes to Editors



About Crescendo Biologics Ltd

Crescendo Biologics is a biopharmaceutical company developing potent, highly differentiated multi-functional Humabody® therapeutics in oncology. It is pursuing novel Humabody®-based product opportunities, through in-house development and strategic partnerships in both multi-functional immuno-oncology modulators and Humabody® Drug Conjugates (HDCs), the next generation of ADCs.

The Company's Humabody® therapeutics are based on its unique, patent protected, transgenic mouse platform generating 100% human V_H domain building blocks (Humabody® V_H) comprising the full structural diversity of the human V_H repertoire and superior biophysical properties as result of their in vivo maturation.

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations), Takeda and Astellas.

For more information, please visit the website: www.crescendobiologics.com.

About Humabody® Therapeutics

Humabodies are a novel class of extremely small, robust and potent protein therapeutics. They are based on fully human V_H domain building blocks (Humabody® V_H) isolated from heavy chain-only antibodies produced using Crescendo's proprietary transgenic mouse.

Compared with monoclonal antibodies, Humabodies® offer a unique combination of potential benefits resulting from their broad structural diversity, small size, high yield and robust biophysical properties. These attributes allow Crescendo to configure an almost limitless range of multi-specific and multi-functional Humabody® formats in a rapid timeframe.

Crescendo is developing a pipeline of novel, Humabody®-based therapeutics in oncology. Next-generation multi-specific Humabody® IO modulators are optimally configured for targeting a range of key mechanisms in the cancer immunity cycle. These include blocking inhibitory signals or activating stimulatory pathways of the immune response as well as specific targeting of IO modulators into the tumor-microenvironment, enhancing antigen presentation and inhibiting the immunosuppressive tumor microenvironment. Humabody® Drug Conjugates (HDCs) demonstrate a superior therapeutic index to standard ADCs.

For more information, please visit the website: www.crescendobiologics.com/humabody.

About the event

Biotech and Money Assembly and Awards is a 250 person Gala Dinner celebrating the UK's funding, finance and investment successes in the sector over the last 12 months. Leading lights and emerging stars, C-suite executives, impactful investors and powerful KOLs in the sector will be celebrating at one of London's finest banqueting halls; Merchant Taylors Hall on 14th September 2017, from 6pm-11pm.

For more information, please visit the website: <http://www.biotechandmoney.com/gala-dinner>